DelveInsight’s, “Metastatic Castration-Resistant Prostate Cancer Pipeline Insight, 2022,” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Metastatic Castration-Resistant Prostate Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Metastatic Castration Resistant Prostate Pipeline Report

• DelveInsight’s Metastatic Castration Resistant Prostate Pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Metastatic Castration Resistant Prostate treatment.
• The leading Metastatic Castration Resistant Prostate Companies includes AstraZeneca, Hinova pharmaceuticals, POINT Biopharma, Exelixis, Tavanta Therapeutics, Pfizer, Zenith Epigenetics, Surface Oncology, Opna-IO LLC, Taiho oncology, Arvinas, Forma therapeutics, ESSA Pharma, Oncternal, Janux Therapeutics, Blue Earth Therapeutics, Arcus Biosciences, Fortis therapeutics, Amgen,  Regeneron Pharmaceuticals, Veru Inc, Constellation Pharmaceuticals, Noxopharm Limited, Immunic AG, Accutar Biotechnology Inc, Hinova pharmaceuticals, Novartis, Nuvation Bio, Bayer, Cardiff Oncology, Astellas Pharma, Hoffman-La-Roche, Modra Pharmaceuticals, Bristol Myers Squibb, Bellicum Pharmaceuticals and others are developing novel drug candidates to improve the metastatic castration-resistant prostate cancer treatment landscape.
• The promising Metastatic Castration-resistant Prostate Cancer therapies in the pipeline and are in various stages of development include Capivasertib, TAVT-45, HC-1119,  PNT2002, Cabozantinib, TAVT-45, ZEN-3694, SRF 617, PLX2853, REGN5678, VERU-100, CPI-1205, NOX66, IMU-935, AC176, HP518, NZV930, NIR178, NUV 422, XL092, VERU-111, BAY2315497, Onvansertib, Enfortumab vedotin, Talazoparib, and others.
• The companies and academics are working to assess challenges and seek opportunities that could influence R&D Metastatic Castration Resistant Prostate cancer. The therapies under development are focused on novel approaches to treat/improve Metastatic Castration Resistant Prostate cancer.

 

Get an overview of the Metastatic Castration Resistant Prostate Pipeline landscape @ Metastatic Castration Resistant Prostate Pipeline Outlook

 

Metastatic Castration Resistant Prostate Overview

Prostate cancer is one of the most prevalent malignancies in the world and the third most common cause of male cancer-related death in the United States of America (USA). The majority of men with newly diagnosed PCa present with localized disease and undergo radical prostatectomy and/or radiological therapy, followed by androgen deprivation therapy (ADT). Depending on the grade of the cancer, a variable percentage of these patients experience progression to castration-resistant prostate cancer (CRPC) within 10 years. CRPC was previously named “hormone-refractory prostate cancer” and “androgen-independent prostate cancer”. However, because castration treatments including ADT were ineffective, these cancers still showed reliance upon hormones for androgen receptor (AR) activation.

 

Latest Breakthroughs and Developments in the Metastatic Castration Resistant Prostate Pipeline Report

• In January 2022, Hinova Pharmaceuticals announced that the first patient with metastatic castration-resistant prostate cancer (mCRPC) had been successfully dosed in Phase I clinical trial of HP518, a highly selective and orally bioavailable chimeric degrader targeting androgen receptor (AR). The ongoing open-label Phase I study in Australia will evaluate the safety, pharmacokinetics, and anti-tumor activity of HP518 in patients with mCRPC.
• In December 2021, Accutar Biotechnology announced the FDA clearance of the IND application for Phase I Trial of AC0176 in prostate cancer. Accutar expects to begin enrollment in Phase 1 clinical trial for AC0176 in the first quarter of 2022.
• In April 2022, Janssen announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of niraparib in combination with abiraterone acetate, in the form of a dual-action tablet plus prednisone, based on the results of the Phase III MAGNITUDE study for the treatment of patients with prostate cancer who have progressed to metastatic castration-resistant prostate cancer (mCRPC) and are positive for homologous recombination repair (HRR) gene alterations. In April 2016, Janssen Biotech, Inc. entered a worldwide (except Japan) collaboration and license agreement with TESARO, Inc. (acquired by GSK in 2018), for exclusive rights to niraparib in prostate cancer.
• In May 2022, Janux Therapeutics announced that the US Food and Drug Administration (FDA) cleared the Company’s investigational new drug (IND) application for its lead product candidate, JANX007, a PSMA-TRACTr in development for the treatment of metastatic castration-resistant prostate cancer (mCRPC). JANX007 is the Company’s lead novel T cell engager (TCE) therapeutic from its TRACTr platform. Janux plans to initiate a Phase I clinical trial for JANX007 in the second half of 2022.
• In June 2022, Blue Earth Therapeutics announced results from a series of preclinical analyses designed to evaluate the biodistribution and potential therapeutic efficacy of 177Lu-rhPSMA-10.1 and 177Lu-PSMA-I&T in the treatment of prostate cancer preclinical models. In April 2022, the FDA cleared an investigational new drug application for 177Lu-rhPSMA-10.1 as a potential therapeutic option for patients with metastatic castration-resistant prostate cancer (mCRPC). 
• Oncternal is supporting an investigator-sponsored study being conducted at the UC San Diego School of Medicine, a Phase Ib clinical trial of  zilovertamab in combination with docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC). In addition, it is also developing ONCT-534, a dual-action androgen receptor inhibitor (DAARI), that is in preclinical development as a potential treatment for castration-resistant prostate cancers, including those with clinically important resistance to approved androgen receptor inhibitors.
• In June 2022, ESSA Pharma Inc. presented clinical results from the Phase Ia dose-escalation study of EPI-7386, ESSA’s first-in-class N-terminal domain androgen receptor inhibitor, as a monotherapy for the treatment of patients with metastatic castration-resistant prostate cancer resistant to current standard-of-care therapies. The initial data from 36 patients demonstrated that EPI-7386 was well-tolerated, exhibited a favorable pharmacokinetic profile, and demonstrated initial anti-tumor activity in a heavily pretreated group of patients. ESSA expects to initiate the Phase Ib expansion study in Q3 2022.
• In May 2022, Arcus Biosciences reported that data analysis from the randomized cohort of ARC-6 evaluating etrumadenant plus zimberelimab and docetaxel versus docetaxel in second-line metastatic castrate-resistant prostate cancer (CRPC) is anticipated in the second half of 2022 with a presentation of results expected in 2023.
• In February 2022, Arvinas reported that the novel androgen receptor (AR) PROTAC degrader, bavdegalutamide (ARV-110), was found to be clinically active and tolerable with manageable adverse effects (AEs) in Phase I/II clinical trial in patients with metastatic castration-resistant prostate cancer (mCRPC) following 1 to 2 prior novel hormonal drugs.
• In March 2022, Forma therapeutics reported positive results from Phase I clinical trial evaluating FT-7051. It was well tolerated with signs of clinical activity and continues to enroll men with metastatic castration-resistant prostate cancer (mCRPC). The first evaluable patient completing 12 weeks of treatment demonstrated a >80% decline in prostate-specific antigen (PSA80) from baseline at 16 weeks with stable disease. As of May 2022, 25 patients were enrolled in the Phase I dose-escalation trial, assessing the predicted efficacious exposure range supported by target engagement.  Future trial enrollment to include less heavily pre-treated patients and alternative dosing schedules to address adverse events, with updated results expected in the first half of 2023.

 

Metastatic Castration Resistant Prostate Emerging Drugs

• SRF617: Surface Oncology
• Rucaparib: Clovis Oncology
• HP518: Hinova Pharmaceuticals

 

Get to know more information about Metastatic Castration Resistant Prostate treatment therapies @ Metastatic Castration Resistant Prostate Clinical Trials

 

Metastatic Castration Resistant Prostate Pipeline Therapeutics Analysis

There are approx. 75+ key companies which are developing the therapies Metastatic Castration Resistant Prostate cancer. The companies which have their Metastatic Castration Resistant Prostate cancer drug candidates in the most advanced stage, i.e phase III include Clovis Oncology

 

DelveInsight’s Metastatic Castration Resistant Prostate Pipeline Report covers around 75+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Discover more about therapy set to grab substantial Metastatic Castration Resistant Prostate Pipeline landscape @ Metastatic Castration Resistant Prostate Market Drivers and Barriers

 

Scope of the Metastatic Castration Resistant Prostate Pipeline Report

• Coverage- Global
• Metastatic Castration Resistant Prostate Companies- AstraZeneca, Hinova pharmaceuticals, POINT Biopharma, Exelixis, Tavanta Therapeutics, Pfizer, Zenith Epigenetics, Surface Oncology, Opna-IO LLC, Taiho oncology, Arvinas, Forma therapeutics, ESSA Pharma, Oncternal, Janux Therapeutics, Blue Earth Therapeutics, Arcus Biosciences, Fortis therapeutics, Amgen,  Regeneron Pharmaceuticals, Veru Inc, Constellation Pharmaceuticals, Noxopharm Limited, Immunic AG, Accutar Biotechnology Inc, Hinova pharmaceuticals, Novartis, Nuvation Bio, Bayer, Cardiff Oncology, Astellas Pharma, Hoffman-La-Roche, Modra Pharmaceuticals, Bristol Myers Squibb, Bellicum Pharmaceuticals, and others
• Metastatic Castration Resistant Prostate Therapies– Capivasertib, TAVT-45, HC-1119,  PNT2002, Cabozantinib, TAVT-45, ZEN-3694, SRF 617, PLX2853, REGN5678, VERU-100, CPI-1205, NOX66, IMU-935, AC176, HP518, NZV930, NIR178, NUV 422, XL092, VERU-111, BAY2315497, Onvansertib, Enfortumab vedotin, Talazoparib, and others
• Metastatic Castration Resistant Prostate Therapeutic Assessment by Product Type
• Metastatic Castration Resistant Prostate Therapeutic Assessment by Stage and Product Type
• Metastatic Castration Resistant Prostate Therapeutic Assessment by Route of Administration
• Metastatic Castration Resistant Prostate Therapeutic Assessment by Stage and Route of Administration
• Metastatic Castration Resistant Prostate Therapeutic Assessment by Molecule Type
• Metastatic Castration Resistant Prostate Therapeutic Assessment by Stage and Molecule Type
• Metastatic Castration Resistant Prostate companies’ collaborations, Licensing, Acquisition -Deal Value Trends
• Metastatic Castration Resistant Prostate – Market Drivers and Barriers

 

Table of Content

1. Introduction
2. Executive Summary
3. Metastatic Castration Resistant Prostate cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Metastatic Castration Resistant Prostate cancer– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Rucaparib: Clovis Oncology
9. Mid Stage Products (Phase II)
10. Surface Oncology: SRF 617
11. Early Stage Products (Phase I/II)
12. REGN 4336: Regeneron Pharamceuticals
13. Early Stage Products (Phase I)
14. HP 518: Hinova Pharmaceuticals
15. Inactive Products
16. Metastatic Castration Resistant Prostate cancer Key Companies
17. Metastatic Castration Resistant Prostate cancer Key Products
18. Metastatic Castration Resistant Prostate cancer- Unmet Needs
19. Metastatic Castration Resistant Prostate cancer- Market Drivers and Barriers
20. Metastatic Castration Resistant Prostate cancer- Future Perspectives and Conclusion
21. Metastatic Castration Resistant Prostate cancer Analyst Views
22. Metastatic Castration Resistant Prostate cancer Key Companies
23. Appendix

 

Got Queries? Reach out for more information on the Metastatic Castration Resistant Prostate cancer Pipeline Report @ Metastatic Castration Resistant Prostate cancer Pipeline Therapeutic Assessment

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Adya Kaul
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/